Document is current
Any future updates will be listed below
-
Authors
Goldman, Jason D https://orcid.org/0000-0002-3825-6832
Robinson, Philip C https://orcid.org/0000-0002-3156-3418
Uldrick, Thomas S https://orcid.org/0000-0001-6959-0924
Ljungman, Per https://orcid.org/0000-0002-8281-3245
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04420364 at ClinicalTrials.govnct04421027 at ClinicalTrials.govDocuments that mention this clinical trial
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
https://doi.org/10.1136/jitc-2021-002630
nct04346199 at ClinicalTrials.govDocuments that mention this clinical trial
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
https://doi.org/10.1136/jitc-2021-002630
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
https://doi.org/10.1136/ard-2023-223850
JAK inhibitors and COVID-19
https://doi.org/10.1136/jitc-2021-002838
IL-6 modulation for COVID-19: the right patients at the right time?
https://doi.org/10.1136/jitc-2020-002285
Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects
https://doi.org/10.1136/rmdopen-2023-004045
nct04492891 at ClinicalTrials.govDocuments that mention this clinical trial
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
https://doi.org/10.1136/jitc-2021-002630
nct04412785 at ClinicalTrials.govDocuments that mention this clinical trial
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
https://doi.org/10.1136/jitc-2021-002630
nct04425538 at ClinicalTrials.govDocuments that mention this clinical trial
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
https://doi.org/10.1136/jitc-2021-002630
nct04583969 at ClinicalTrials.govDocuments that mention this clinical trial
COVID-19 and IBD drugs: should we change anything at the moment?
https://doi.org/10.1136/gutjnl-2020-323247
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
https://doi.org/10.1136/jitc-2021-002630
Documents that mention this clinical trial
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
https://doi.org/10.1136/jitc-2021-002630
- License Information
